<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623930</url>
  </required_header>
  <id_info>
    <org_study_id>P.T.REC/012/004116</org_study_id>
    <nct_id>NCT05623930</nct_id>
  </id_info>
  <brief_title>Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver</brief_title>
  <official_title>Hepatic Enzymes and Metabolic-Risk Factors Responses to Laser Acupuncture Versus Cupping Therapy in Fatty Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism,&#xD;
      cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver&#xD;
      enzymes)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In fatty liver patients,applied cupping (with scarification) will be compared, regarding its&#xD;
      effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures&#xD;
      (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2022</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>high density lipoprotein</measure>
    <time_frame>12 weeks</time_frame>
    <description>it is a component of lipid profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>it is a component of lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low density lipoprotein</measure>
    <time_frame>12 weeks</time_frame>
    <description>it is a component of lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>it is a component of lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>fasting level of blood glucose will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>12 weeks</time_frame>
    <description>high sensitivity levels C reactive protein will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>12 weeks</time_frame>
    <description>it ts oxidative stress marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aspartate transaminase</measure>
    <time_frame>12 weeks</time_frame>
    <description>it is a hepatic enzyme that reports the functions of liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine transaminase</measure>
    <time_frame>12 weeks</time_frame>
    <description>it is a hepatic enzyme that reports the functions of liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>it will be measured by sphygmomanometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>it will be measured by sphygmomanometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>it will be measured manually</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>laser on acupuncture points</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cupping (with scarification)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>laser acupuncture</intervention_name>
    <description>In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian</description>
    <arm_group_label>laser on acupuncture points</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>wet cupping</intervention_name>
    <description>in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.</description>
    <arm_group_label>cupping (with scarification)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  fatty liver obese patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        thoracic diseases heart diseases kidney diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>based on self-representation of gender identity.</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Ismail, lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali Ismail, lecturer</last_name>
    <phone>02 01005154209</phone>
    <email>ali.mohamed@pt.cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ahmed Elfahl, Lecturer</last_name>
    <email>ahmed.elfahl@buc.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo Unoversity</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Ismail, lecturer</last_name>
      <phone>01005154209</phone>
      <email>allooka2012@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 18, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>November 18, 2022</last_update_submitted>
  <last_update_submitted_qc>November 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ali Mohamed Ali ismail</investigator_full_name>
    <investigator_title>lecturer of Physical Therapy for Cardiovascular / Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

